How can AI help uncover new treatments for Parkinson's disease?

Oct 18, 2018

How can AI help uncover new treatments for Parkinson's disease?

Tagged:

It’s been 50 years since the last treatment for Parkinson’s disease has been developed - patients are waiting too long for better treatments. We believe the application of AI holds huge potential to accelerate work towards a research breakthrough in Parkinson’s.

We believe this is possible through combining the extensive knowledge of charities, such as The Cure Parkinson’s Trust, alongside our platform - a machine intelligence technology system built to mine new knowledge. In this video, Dr. Jackie Hunter explores how we can take a different approach to solve highly specific, complex research challenges and why the UK is a fantastic hub to do it.

More Posts

You Might Also Like

Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job

At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.

Oct 17, 2021

BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies

BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.

Oct 14, 2021

Measuring bias: moving towards more inclusive health research outcomes #stateofai

Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.

Oct 12, 2021

Expert-augmented computational drug discovery for rare diseases

Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.

Sep 28, 2021

BenevolentAI appoints Dr John Orloff to its Board of Directors

Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.

Sep 9, 2021

AI in Drug Discovery

This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.

Jul 13, 2021